AgomAb Therapeutics NV

AgomAb Therapeutics NV

NNASDAQ:AGMB
5.97
USD
-0.39
(-6.13%)
639.24MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of June 30, 2026, AgomAb Therapeutics NV carries a market capitalization of 639.24M, placing it among publicly traded companies globally. Its enterprise value stands at 352.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap639.24M
Enterprise Value352.66M

Important Dates

AgomAb Therapeutics NV's next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, AgomAb Therapeutics NV has 49.25M shares outstanding.

Shares Outstanding49.25M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio2.11
P/TBV Ratio2.36

Financial Position

As of June 30, 2026, AgomAb Therapeutics NV maintains a current ratio of 12.88, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities.

Current Ratio12.88
Quick Ratio12.55
Debt / Equity0.43

Financial Efficiency

These figures cover the twelve months ended June 30, 2026.

Employee Count62.00

Stock Price Statistics

USD

These figures are as of the close on November 16, 2026.

50-Day Moving Average9.38

Balance Sheet

USD

As of June 30, 2026, AgomAb Therapeutics NV holds 287.88M in cash and equivalents against 1.30M in total debt, resulting in a net debt position of -253.16M. Total book value stands at 303.18M, with working capital of 272.38M providing operational flexibility.

Cash & Cash Equivalents287.88M
Total Debt1.30M
Net Debt-253.16M
Equity (Book Value)303.18M
Book Value Per Share6.16
Working Capital272.38M

Cash Flow

USD

These figures cover the twelve months ended June 30, 2026.

Capital Expenditures-4,569.86